Parkinson’s disease is a chronic progressive neurodegenerative condition. It damages central nervous system dopaminergic but also serotonergic and noradrenergic pathways. There is no known cure, and no existing therapy has been proven to slow or reverse progress of the disease. Treatment aims to alleviate symptoms and preserve functional independence while minimising adverse affects.
Get full access to this article
View all access options for this article.
References
1.
National Institute for Health and Clinical Excellence. Parkinson’s disease: diagnosis and management in primary and secondary care. London: NICE; 2006. Available from: http://www.nice.org.uk/guidance/CG35.
2.
StoweRLIvesNJClarkeC Dopamine agonist therapy in early Parkinson’s disease. Cochrane Database Syst Rev 2008; 2:CD006564.
3.
MacleodADCounsellCEIvesN Monoamine oxidase B inhibitors for early Parkinson’s disease. Cochrane Database Syst Rev 2005; 3:CD004898.
4.
NyholmDAINilsson RemahlDizdarNDuodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology2005; 64:216–23.
5.
ClarkeCESpellerJMClarkeJA.Pramipexole for levodopainduced complications in Parkinson’s disease. Cochrane Database Syst Rev 2000; 2:CD002261.
6.
ClarkeCEDeaneKHO.Ropinirole for levodopa-induced complications in Parkinson’s disease. Cochrane Database Syst Rev 2001; 1:CD001516.
7.
SteigerM.Constant dopaminergic stimulation by transdermal delivery of dopaminergic drugs: a new treatment paradigm in Parkinson’s disease. Eur J Neurol2008; 15:6–15.
8.
PahwaRStacyMAFactorSARopinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology2007; 68:1108–15.
9.
DeaneKHOSpiekerSClarkeCE.Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson’s disease. Cochrane Database Syst Rev 2004; 4:CD004554.
10.
MyllyläV.L15 Clinical trials with catechol-O-methyltransferase (COMT) inhibitors, entacapone and tolcapone. Eur J Pharm Sci 2008; 1:Suppl 1:13.
11.
DeuschlGSchade-BrittingerCKrackP A randomized trial of deep-brain stimulation for Parkinson’s disease. N Engl J Med 2006; 355(9):896–908. Erratum in: N Engl J Med 2006; 355(12):1289.
12.
FreedCRGreenePEBreezeRETransplantation of embryonic dopamine neurons for severe Parkinson’s disease. N Engl J Med2001; 344:710–9.
13.
OlanowCWGoetzCGKordowerJHA double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson’s disease. Ann Neurol2003; 54:403–14.
14.
MasterZMcLeodMBenefitsMendez I.risks and ethical considerations in translation of stem cell research to clinical applications inParkinson’s disease. J Med Ethics2007; 33:169–73.
15.
KaplittMFeiginATangCSafety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson’s disease: an open label, phase I trial. Lancet2007; 369:2097–105.
